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Abstract
Objective—Monogenic diabetes, a young-onset form of diabetes, is often misdiagnosed as Type 
1 diabetes, resulting in unnecessary treatment with insulin. A screening approach for monogenic 
diabetes is needed to accurately select suitable patients for expensive diagnostic genetic testing. 
We used C-peptide and islet autoantibodies, highly sensitive and specific biomarkers for 
discriminating Type 1 from non-Type 1 diabetes, in a biomarker screening pathway for monogenic 
diabetes.
Research Design and Methods—We studied patients diagnosed ≤30y, currently <50y, in two 
UK regions with existing high detection of monogenic diabetes. The biomarker screening pathway 
comprised 3 stages: 1) Assessment of endogenous insulin secretion using urinary C-peptide/
creatinine ratio (UCPCR); 2) If UCPCR≥0.2nmol/mmol, measurement of GAD and IA2 islet 
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autoantibodies; 3) If negative for both autoantibodies, molecular genetic diagnostic testing for 35 
monogenic diabetes subtypes.
Results—1407 patients participated (1365 no known genetic cause, 34 monogenic diabetes, 8 
cystic-fibrosis-related diabetes). 386/1365(28%) had UCPCR≥0.2nmol/mmol. 216/386(56%) of 
these patients were negative for GAD and IA2 and underwent molecular genetic testing. 17 new 
cases of monogenic diabetes were diagnosed (8 common MODY (Sanger sequencing), 9 rarer 
causes (next generation sequencing)) in addition to the 34 known cases (estimated prevalence of 
3.6% (51/1407) (95%CI: 2.7-4.7%)). The positive predictive value was 20%, suggesting a 1-in-5 
detection rate for the pathway. The negative predictive value was 99.9%.
Conclusions—The biomarker screening pathway for monogenic diabetes is an effective, cheap, 
and easily implemented approach to systematically screening all young-onset patients. The 
minimum prevalence of monogenic diabetes is 3.6% of patients diagnosed ≤30y.
Registered on Clinicaltrials.gov ref NCT01238380
Introduction
Correct classification of a patient’s diabetes is important to ensure they receive the most 
appropriate treatment and ongoing management. The most common form of diabetes in 
children and young adults is Type 1 diabetes, accounting for over 90% of cases(1; 2). Other 
forms of diabetes in this age group, such as monogenic diabetes (including Maturity Onset 
Diabetes of the Young (MODY)), or young-onset Type 2, are not often considered. It is 
estimated that at least 80% of patients with MODY are misdiagnosed(3), and other rarer 
forms of monogenic diabetes often go unrecognized due to lack of awareness(4). Patients 
with MODY or Type 2 diabetes misclassified as Type 1 diabetes will be treated with insulin, 
whereas non-insulin therapy would be more appropriate. Diet and metformin are the 
treatment of choice in young Type 2 diabetes(5). Patients with MODY due to mutations in 
the HNF1A or HNF4A genes respond well to low dose sulphonylureas(6; 7) and those with 
MODY due to mutations in the GCK gene require no pharmacological treatment(8). Getting 
a correct diagnosis for all forms of monogenic diabetes has important implications for 
management of an individual’s diabetes, their prognosis, and recognition of associated 
clinical features; it also allows appropriate counselling of other family members regarding 
likely inheritance (4).
Identifying patients with monogenic diabetes, particularly MODY, can be challenging. 
Monogenic diabetes is confirmed by molecular genetic testing, but this is expensive so 
testing all patients is not feasible. An approach that could be used to enrich for monogenic 
diabetes, increasing the proportion identified in those who undergo genetic testing, would be 
helpful. Clinical features can aid identification of those who may have an alternative 
diagnosis, and a probability calculator has been developed to help determine which patients 
are likely to have the most common forms of MODY(9). However, this will not pick up 
other forms of monogenic diabetes and its performance is weaker for detecting MODY in 
insulin treated patients compared to non-insulin treated patients.
An alternative approach to enrich for monogenic diabetes is to use biomarkers which have 
been shown to discriminate well between Type 1 and other forms of young onset diabetes. 
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Type 1 diabetes is characterized by autoimmune destruction of the beta-cells in the pancreas 
leading to absolute insulin deficiency so two tests that could be used to diagnose Type 1 
diabetes are islet autoantibodies (markers of the autoimmune process) and C-peptide (a 
marker of insulin deficiency). C-peptide has been shown to be a highly sensitive and specific 
biomarker for discriminating between Type 1 and Type 2 diabetes and MODY 3-5 years 
after diagnosis(10; 11). Urine C-peptide-Creatinine ratio (UCPCR) can be used to remove 
the need for blood samples, which may be of particular concern in the pediatric population, 
and means that the sample can easily be taken at home and posted to the laboratory(12). 
GAD and IA2 islet autoantibodies also discriminate well between Type 1 and MODY, with 
cross sectional studies showing they are present in 80% of patients with Type 1 diabetes and 
in less than 1% of patients with MODY(13). These biomarkers have been used to screen for 
MODY in other studies(14; 15), but have been limited to pediatric cases only. Given the 
median age at diagnosis for MODY is 20 years (from UK referrals data(3)), and there is on 
average a delay of 13 years from diabetes diagnosis to a confirmed genetic diagnosis(16), it 
is crucial to study adults as well. Furthermore the combined diagnostic performance of the 
two biomarkers as a screening pathway has not been formally assessed.
By excluding those with Type 1 diabetes using these two biomarkers we can obtain a smaller 
percentage of patients in whom diagnostic molecular testing for monogenic diabetes could 
be performed. We tested a screening pathway using both C-peptide and islet autoantibodies 
to exclude Type 1 diabetes in two populations with previously high pick-up rates of 
MODY(3), and performed genetic testing on all patients with significant endogenous insulin 
and absence of islet autoantibodies. This allowed us to determine the prevalence of all 
monogenic diabetes subtypes in those diagnosed ≤30 years, and to calculate the positive and 
negative predictive values for the pathway.
Research Design and Methods
Subjects
Patients diagnosed aged 30 years or under, and currently aged under 50, in the catchment 
areas of the Royal Devon and Exeter NHS Foundation Trust (Exeter, UK) and Ninewells 
Hospital (Dundee, UK) were invited to take part in the study via the doctors looking after 
their medical care. All patients with diabetes in this age group were eligible regardless of 
cause. Both regions had existing high pick-up rates for MODY prior to the study due to 
research interests(3). Patients that consented provided samples as part of the biomarkers 
screening pathway (the UNITED study (Using pharmacogeNetics to Improve Treatment in 
Early-onset Diabetes (UNITED)), clinicaltrials.gov ref NCT01238380).
Biomarker Screening Pathway
All recruited patients followed the biomarker screening pathway (Figure 1):
1. Assessment of endogenous insulin, in insulin treated patients, using urinary C-
peptide creatinine ratio (UCPCR)
A key determinant of requirement for insulin treatment is lack of endogenous 
insulin secretion, and UCPCR is an easy screening test that can be done at home. 
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UCPCR was used to rule out the majority of Type 1 patients in the first stage of 
screening, with minimal patient burden.
Insulin treated patients were asked to collect a urine sample two hours after the 
largest, carbohydrate containing meal of the day and to post this direct to the 
laboratory in a pack provided to allow analysis within 72 hours of sample 
collection, in line with assay stability(12).
Urinary C-peptide was measured by an electrochemiluminescence immunoassay 
(intra-assay coefficient of variation, 3.3%; interassay coefficient of variation, 
4.5%) on a Roche Diagnostics E170 analyzer (Mannheim, Germany)(12). The 
lower limit of the C-peptide assay was 0.03nmol/l. Urinary creatinine was 
analyzed on the Roche P800 platform using creatinine Jaffé reagent 
(standardized against isotope dilution mass spectrometry) and used to calculate 
UCPCR (nmol/mmol). Patients with UCPCR≥0.2nmol/mmol were considered to 
have significant endogenous insulin secretion(10).
2. Islet autoantibody measurement in patients with significant endogenous insulin
Islet autoantibodies (GAD and IA2) were measured in patients who tested 
positive for UCPCR (UCPCR≥0.2nmol/mmol) or who were non-insulin treated. 
In order to minimize taking blood samples, particularly in children, the local 
pathology databases were checked for previous GAD and IA2 results and these 
were used if available. Patients with no previous islet autoantibody results were 
invited to attend an appointment with the study’s research nurse to provide blood 
samples for islet autoantibody testing and DNA.
GAD and IA2 antibody analysis was performed using commercial ELISA assays 
(RSR Ltd., Cardiff, UK) and a Dynex DSX automated ELISA system (Launch 
Diagnostics, Longfield, UK)(13). Both methods are highly specific and sensitive, 
(GAD antibodies 98% and 84% and IA-2 antibodies 99% and 74%, 
respectively). The laboratory participates in the Diabetes Autoantibody 
Standardization Programme. Patients were considered positive for antibodies if 
their results were >99th centile (64 WHOunits/ml for GAD and 15 WHOunits/ml 
for IA2)(13).
3. Diagnostic molecular genetic testing for monogenic diabetes in patients with 
significant endogenous insulin and negative antibody results
a) Sequencing of three MODY genes, the most common forms of 
monogenic diabetes.
For all patients who were negative for both GAD and IA2 antibodies 
with significant endogenous insulin, DNA sequencing of HNF1A, 
HNF4A and GCK was performed by PCR amplification of purified 
genomic DNA, followed by Sanger DNA sequencing of each gene’s 
exons and flanking intronic regions. Dosage analysis of HNF1A, 
HNF4A and GCK for partial and whole gene deletions was also 
performed by multiplex ligation-dependent probe amplification 
(MLPA) using the MRC-Holland MODY MLPA kit-P241-B1.
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b) Targeted next generation sequencing for 35 genes in which mutations 
are known to cause monogenic diabetes. If no pathogenic mutation was 
identified in HNF1A, HNF4A or GCK, further targeted next generation 
sequencing was performed for mutations in 35 monogenic diabetes 
genes (all genes where mutations are known to cause MODY, neonatal 
diabetes, and other genetic diabetes syndromes), using a custom 
Agilent SureSelect exon-capture assay (Agilent Technologies, Santa 
Clara, CA, USA)(17) (see supplemental materials and Supplemental 
Table S1 for methodology, sensitivity and details of genes tested).
Statistical analysis
For comparing new cases diagnosed through the screening pathway to known cases of 
monogenic diabetes, and for comparing the biomarker screening pathway with an approach 
using clinical features (including the MODY probability calculator(9)) to detect monogenic 
diabetes, variables were categorical and so chi-squared and Fisher’s exact tests were used.
Prevalence of MODY—The prevalence of MODY in this population was determined as 
the proportion of positive cases, (including both known MODY that were recruited and those 
identified through the study), out of the total recruited.
To determine whether there was any potential bias in recruitment of MODY patients that 
may affect our prevalence estimate, we also obtained summary data on the number of 
patients with previously confirmed monogenic diabetes in each study area who had not been 
recruited into this study.
Positive and Negative Predictive Values of Pathway—Calculating the prevalence in 
this population allows us to determine the positive and negative predictive values for the 
pathway, the most important statistics for the clinician. Positive and negative predictive 
values were calculated as:
where pre-test odds is prevalence/(1-prevalence) and positive likelihood ratio is 
sensitivity/(1-specificity). Positive predictive value (PPV; equivalent to post-test probability) 
is post-test odds/(1+post-test odds). Negative predictive value (NPV) was calculated 
similarly, but using a negative likelihood ratio (1-sensitivity/specificity), with negative post-
test probability equal to 1 - NPV. Number needed to test was calculated as 1/PPV.
Performance of the pathway – sensitivity and specificity—The key question is 
how well, if applied to a whole population, do the biomarkers perform in a pathway for 
identifying new cases. Screening literature emphasises the difference between programme 
sensitivity/specificity and test sensitivity/specificity, where assessing the sensitivity/
specificity of a screening programme such as this, necessarily requires approximation using 
multiple data sources(18). As this was a population based study, rather than a case-control 
study, formal assessments of sensitivity and specificity (as normally conducted using a 2x2 
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table) of the pathway were limited due to the rarity of monogenic diabetes (meaning a small 
sample size of true positive cases of monogenic diabetes), and the expense of genetic testing 
(restricting confirmation of all the true negative non-monogenic cases).
Assessments of sensitivity of the components of the pathway for detecting monogenic 
diabetes have been carried out in larger case control cohorts (n=508 monogenic diabetes 
cases for islet autoantibodies (99% sensitivity)(13), n=160 for UCPCR (99% sensitivity, 
both studies combined(10; 11))), so it is more appropriate to use these estimates. We 
assumed a 98% sensitivity for both combined, based on these larger studies (assuming 1% 
missed due to false negative UCPCR and 1% due to false positive islet autoantibodies). 
However, the detection rate in all true monogenic cases in this pathway will be calculated for 
comparison.
Calculation of the specificity is limited as we have not performed genetic testing on all C-
peptide negative patients. Previous larger studies have shown <1% of patients are missed(10; 
11; 13). However, specificity of the biomarkers in these studies was assessed using gold 
standard Type 1 diabetes as the comparison group, rather than all non-MODY patients in this 
age range, and so likely overestimates the performance due to spectrum bias(19). We 
therefore, calculated specificity based on one minus the false positive rate of the pathway 
(i.e. proportion UCPCR positive/antibody negative, but not having a confirmed diagnosis of 
monogenic diabetes on subsequent genetic testing). This assumes all patients negative 
according to the pathway are true negatives. As an additional test of this assumption, a 
subset of patients negative for islet autoantibodies received genetic testing for the 3 main 
MODY genes and the proportion of MODY was calculated.
Health economic evaluation of the pathway is addressed in a separate paper (Peters et al. 
manuscript under review, protocol and conference abstract available(20; 21)).
Results
Subjects
The flow of subjects through the study is shown in Figure 2. 2288 patients were eligible in 
area and 1418 subjects (62%) in total consented to the study and were recruited: 716 from 
the Exeter area, 702 from Dundee. 11 patients dropped out (9 did not provide blood samples 
for antibody testing, and 2 did not provide samples for DNA testing). Of the 1407 remaining 
patients, 1365 had no known genetic cause for their diabetes. Characteristics of these 
patients are shown in Supplemental Table S2 and subsequent results on the screening 
pathway are based on these patients. 42 patients had a known genetic cause for their diabetes 
prior to participating in this pathway: 34 patients had confirmed monogenic diabetes (see 
Table 2 for details) and 8 patients had Cystic-fibrosis related diabetes.
Biomarker screening pathway identifies 17 new cases of monogenic diabetes (Figure 2)
Excluding drop-outs, 1281 (94%) of 1365 patients with no known genetic cause for their 
diabetes were insulin treated and provided a sample for UCPCR testing. 2 patients were 
anuric due to renal failure and so went straight on to antibody testing. 979 of these patients 
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(76%) had minimal endogenous insulin secretion (UCPCR <0.2nmol/mmol) indicating a 
diagnosis of Type 1 diabetes, so received no further testing
Islet autoantibodies were tested in the 84 non-insulin treated patients, 300 UCPCR positive 
patients, and the 2 anuric patients. 170/386 (44%) tested positive for GAD and/or IA2 
antibodies, confirming islet autoimmunity and hence a diagnosis of Type 1 diabetes. So 
these patients received no further testing.
Sanger sequencing for the 3 commonest MODY genes was undertaken in 216 patients (16% 
of the whole cohort). 8 patients tested positive confirming a diagnosis of MODY: 5 HNF1A, 
2 HNF4A, and 1 GCK (Table 1, Figure 2).
Of the 208 who tested negative for the common MODY genes, additional testing by targeted 
next generation sequencing identified mutations in genes associated with monogenic 
diabetes in a further 8 patients and 1 patient had a mutation in POLD1 identified through 
exome sequencing (see Table 1, Figure 2).
New cases of monogenic diabetes identified were more likely to be rarer causes and 
atypical (Supplemental Figure S1)
More of the new cases of monogenic diabetes identified had mutations in genes other than 
the 3 most common forms of MODY. (25/34 (74%) of those diagnosed prior to the study had 
mutations in HNF1A, HNF4A, or GCK compared with 8/17 (47%) identified from Sanger 
sequencing as part of the biomarker screening pathway, p=0.06). Those diagnosed with 
monogenic diabetes as part of the study were less likely to have a parent known to be 
affected than those with a previous known monogenic diagnosis (8/17 (47%) v 29/34 (85%), 
p=0.007).
Minimum prevalence of monogenic diabetes of 3.6% in those diagnosed <30y, currently 
under 50y
We found 51 cases of monogenic diabetes (which represents a further 50% (n=17) in 
addition to the 34 previously diagnosed) out of 1407 recruited patients providing a 
prevalence of 3.6% (95% CI: 2.7 to 4.7%) in patients diagnosed under 30 and currently 
under 50 years.
From the database of UK referrals, we identified 26 patients with a diagnosis of monogenic 
diabetes in the Exeter and Tayside regions, who met study inclusion criteria, but were not 
recruited to the UNITED study. Therefore, the proportion of known monogenic diabetes 
prior to the study in the recruited population (34/1407 (2.4%)) was similar to the proportion 
in the non-recruited population (26/870 (3.0%)) (p=0.4), suggesting no overall bias in 
recruitment. More of the non-recruited cases had MODY caused by mutations in the GCK 
gene but this was not significant given the small numbers (46% v 26%, p=0.1). There was no 
difference in terms of age at diagnosis (mean 18 v 19y, p=0.5), age at time of recruitment 
(using 2011 for non-recruited patients) (32 v 32y, p=0.98) or gender (35% v 45% male, 
p=0.4).
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Performance of the pathway (Table 2)
In line with what was expected given larger studies of the diagnostic accuracy of UCPCR 
and islet autoantibodies and the known pathophysiology of monogenic diabetes, all cases 
with previously diagnosed monogenic diabetes who provided all samples for the pathway 
(n=21) were UCPCR positive and antibody negative. Similarly, all antibody positive patients 
with DNA available (n=47) tested negative for the three main MODY genes so no additional 
MODY cases were picked up in this group.
199/1348 (15%) of patients were put forward for genetic testing who were not found to have 
monogenic diabetes (i.e. 15% false positive rate, so 85% specificity). Assuming a 98% 
sensitivity and 85% specificity, the positive predictive value for the pathway is 20%, 
suggesting a 1 in 5 pick-up rate for monogenic diabetes, a 5.6-fold increase in probability 
over the background prevalence alone. The negative predictive value was 99.9%, indicating 
the probability of having monogenic diabetes if you are UCPCR negative or islet 
autoantibody positive is 0.1% (1 in 1000).
Comparison of biomarker screening pathway with clinical features (Table 2)
If genetic testing had been limited to the standard clinical criteria for MODY (age at 
diagnosis <25y, non insulin requiring and a parent known to be affected with diabetes), 
fewer patients would have required testing (n=33) leading to a higher pick-up rate and 
positive predictive value (PPV=57.6%) than the biomarker pathway, but the majority of 
monogenic cases would have been missed (63% compared with 0% for the biomarker 
pathway). The MODY probability calculator also had a higher positive predictive value 
(PPV=40.4%), but missed more cases (55%) compared with the biomarker pathway.
Conclusions
The biomarker screening pathway for monogenic diabetes is a systematic, cheap (UK 
UCPCR cost=£10.80, antibodies cost=£20), and easily implemented approach to screening 
all patients with young-onset diabetes in a clinic or population that helps identify suitable 
patients for molecular diagnostic genetic testing. The pathway picked up new cases of 
monogenic diabetes, even in areas of existing high detection due to research interests in the 
regions. We found 3.6% of patients diagnosed less than 30 years of age have monogenic 
diabetes. In areas where no cases have been identified, we estimate that 1 in 5 patients 
referred for genetic testing as a result of the pathway will have monogenic diabetes which is 
a 5.6-fold higher detection rate than if all patients in this age range received genetic testing. 
The high negative predictive value of 99.9% indicates it is an extremely effective approach 
for ruling out monogenic diabetes.
There have been relatively few studies that have systematically screened whole populations 
for monogenic diabetes. The majority of studies have been in pediatric populations only(14; 
15; 22–26), with only two studies that have screened adults(27; 28). No other study has 
systematically screened a whole population of both adults and children together. Only 8/51 
(16%) of patients with a genetic diagnosis of monogenic diabetes in our cohort were in the 
pediatric age range (<20y) at the time of recruitment, highlighting the importance of looking 
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for monogenic diabetes in adult diabetes clinics. This may explain why the prevalence we 
find is higher than any of the previous pediatric studies.
The strength of our pathway is the integration of two biomarkers (C-peptide and islet 
autoantibodies (both GAD and IA2)), rather than relying on clinical features. This offers a 
simple approach that does not require specific clinician interpretation or complex algorithms 
of different combinations of features. We showed that by using clinical features alone over 
half the cases of monogenic diabetes would be missed. By combining the two biomarkers 
we increase the discriminatory ability and allow the clinician to pick up even atypical cases 
and rarer forms of monogenic diabetes, which traditional criteria may miss. The use of 
clinical features, however, results in fewer cases being sent for genetic testing that are 
negative, which clearly has cost implications. The most cost effective approach is likely to 
involve a combination of biomarkers and clinical features. Further studies are needed to 
determine whether the pick-up rate could be further improved by integrating the pathway 
with clinical features, such as the MODY calculator, or whether this would result in more 
missed patients as a consequence of reduced testing.
In this study we also systematically tested all known genes for monogenic diabetes, rather 
than just the most common MODY genes (GCK, HNF1A and HNF4A). 9/17 (53%) of the 
cases identified as part of our cohort had mutations identified through additional testing on 
the targeted capture and 17/51 (33%) of all the monogenic diabetes cases found in total had 
mutations in other genes, highlighting the advantage of further testing using targeted next 
generation sequencing.
Health economic evaluation of the pathway for detecting the common forms of MODY 
(GCK, HNF1A and HNF4A) has been carried out as a separate project, which has shown the 
pathway to be cost-saving (Peters et al, manuscript under review, abstract/protocol 
available(20; 21)). The cost-effectiveness of additional testing for other forms of monogenic 
diabetes has not been assessed. Due to the rarity of other monogenic diabetes there are little 
data available to inform such analyses. Treatment change from insulin to sulphonylureas is 
still possible in cases diagnosed with ABCC8 and KCNJ11(29; 30), and for other genes 
where treatment change is not an option, a confirmed diagnosis can still help with 
management, prognosis and advice on risk to other family members(4). The decision 
whether to pay for the more expensive, but more comprehensive next generation sequencing, 
rather than Sanger sequencing for MODY genes only, would depend on assessing the trade-
offs of additional costs with long term benefits to the patient. The presence of additional 
clinical features (e.g. renal cysts associated with HNF1B) may also point to specific 
monogenic diagnoses and increase the likelihood of a positive genetic test result.
A limitation of our study was that we had small numbers of patients with monogenic 
diabetes on which to evaluate the sensitivity of the pathway. Considerably larger studies 
have shown the biomarkers individually to be highly sensitive for monogenic diabetes (99% 
for UCPCR(10; 11) and >99% for islet autoantibodies(13)), and by using both of these 
markers in a pathway the number of missed cases should be minimal at a population level 
(2% of 3.6% = 0.07%, reflected in the NPV of 99.9%). Although there have been reports of 
MODY patients who are positive for islet autoantibodies (reviewed in (13)), these are rare 
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and are likely to be cases with coincidental Type 1 diabetes. Previous studies reporting high 
prevalence of positive autoantibodies in their cohort have included clinically defined, rather 
than genetically confirmed MODY(31) or use low cutoffs for antibody positivity, which can 
be inappropriate(32), so are likely to represent an overestimate. There is also the potential 
for missed cases based on UCPCR, but again, the number of these patients will be small, and 
as they have insulin levels suggestive of Type 1 diabetes(33) they are unlikely to be able to 
transfer off insulin even if a genetic diagnosis is made.
A further limitation is that despite screening using C-peptide and antibody testing the 
positive predictive value is still fairly low at 20%, indicating 4 out of 5 screened will not 
have a monogenic cause identified on diagnostic molecular genetic testing. However, the 
aim of our screening pathway is that it is used purely as a tool to narrow down those 
individuals who would be more appropriate for genetic testing. This approach is a vast 
improvement over no screening (which would represent a PPV at the background prevalence 
rate of 3.6%), misses fewer cases than using clinical features alone, and is at a level that has 
been shown to be cost-effective (manuscript under review, protocol and abstract 
available(20; 21)). Furthermore, the screening pathway still provides useful test results for 
this age group that offer additional information to support patient care. Patients with severe 
insulin deficiency as determined by very low C-peptide values, will not respond to non-
insulin therapy(33). Positive C-peptide and negative antibody results are important clinically 
to highlight atypical cases of Type 1 diabetes or where other forms of diabetes, such as 
young-onset Type 2 diabetes should be considered. Patients with very high endogenous 
insulin without islet autoantibodies and no mutations in monogenic diabetes genes, are likely 
to have Type 2 diabetes, and may be able to manage on non-insulin treatment.
Finally, this study comprised a 98% White Caucasian population and assesses patients at a 
median of 14 years after diagnosis. Assessment of the pathway in other racial groups and in 
patients close to diagnosis is needed.
In conclusion, we have demonstrated a simple, cheap, effective screening pathway that could 
be implemented at a population level to help correctly diagnose patients with monogenic 
diabetes.
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Figure 1. 
The UNITED biomarker screening pathway to investigate etiology of diabetes in patients 
diagnosed ≤30y: Genetic testing is carried out on all patients who have endogenous insulin 
(UCPCR≥0.2nmol/mmol) and who do not have either GAD or IA2 islet autoantibodies. 
Patients without endogenous insulin or have GAD and/or IA2 islet autoantibodies are 
classed as having Type 1 diabetes.
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Figure 2. 
Flow chart of patients recruited as part of UNITED. Biomarker screening pathway in 1376 
patients with no known genetic cause for their diabetes in Exeter and Tayside. 11 dropped 
out. 17 new cases of monogenic diabetes detected (*one case identified through exome 
sequencing)
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